Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-06-08
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 11850000 NOK
Award criteria: Lowest price

Technical requirements: Voluntary ex-ante transparency notice - supplementary contract LIS2201a Aciklovir infusion 25mg/ml 10ml and 20ml
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for parenteral special pharmaceutical preparations (LIS 2201a). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
There was only one tenderer that submitted a tender for the sub-delivery in question (sub-delivery 129, ATC code J05AB01, Aciklovir, infusion). After the contract was signed, the tenderer notified us that they cannot deliver, and the contract was terminated. Therefore there is a need to enter into a new contract.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for parenteral special pharmaceutical preparations (LIS 2201a). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
There was only one tenderer that submitted a tender for the sub-delivery in question (sub-delivery 129, ATC code J05AB01, Aciklovir, infusion). After the contract was signed, the tenderer notified us that they cannot deliver, and the contract was terminated. Therefore there is a need to enter into a new contract.
Due to this, LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Pfizer AS (the Supplier) as an additional contract to LIS 2201a, i.e., the scope and length of the contract must follow the mentioned procurement (including access to extensions and terminations), without a new competition being held for this ingredient. The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region.
LIS has explored the market situation and is of the opinion that it is impossible to hold a new contest, or that a supplier other than Pfizer AS can deliver the product in the imminent contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS [the Pharmaceutical Division] therefore believes that there are grounds to make the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that any objections to this intention are submitted before the expiry of the waiting period, set to 12.06.2022. If no objections are received, contracts will be signed after the waiting period has expired.
LIS has explored the market situation and is of the opinion that it is impossible to hold a new contest, or that a supplier other than Pfizer AS can deliver the product in the imminent contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS [the Pharmaceutical Division] therefore believes that there are grounds to make the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.


Winner: Pfizer AS
Award value: 11850000